U.S. markets closed

Pfizer Inc. (PFE)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
33.75-0.16 (-0.47%)
At close: 4:02PM EST

33.83 +0.08 (0.24%)
After hours: 7:59PM EST

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
MACD

MACD

Previous Close33.91
Open33.87
Bid33.80 x 1000
Ask33.81 x 4000
Day's Range33.67 - 34.05
52 Week Range26.45 - 43.08
Volume29,848,976
Avg. Volume42,057,736
Market Cap187.596B
Beta (5Y Monthly)0.63
PE Ratio (TTM)19.77
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield1.56 (4.60%)
Ex-Dividend DateJan 28, 2021
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
-14% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Reuters

    English survey finds high antibody levels from Pfizer vaccine roll-out

    People in England who have received two doses of Pfizer COVID-19 vaccine are generating strong antibody responses as the shot is rolled out, researchers said on Thursday, adding that confidence in vaccines was high. An Imperial College London survey showed 87.9% of people over the age of 80 tested positive for antibodies after two doses of the Pfizer-BioNTech vaccine, rising to 95.5% for those under the age of 60 and 100% in those aged under 30. "Although there is some fall-off in positivity with age, at all ages, we get that very good response to two doses of the vaccine," Paul Elliott, Chair in Epidemiology and Public Health Medicine, Imperial College London, told reporters.

  • Barrons.com

    How Pfizer Plans to Combat Covid-19 Variants

    Pfizer's chief scientist said it was imperative for countries to work together to identify Covid-19 variants taking hold in vaccinated people.

  • Reuters

    In boost for COVID-19 battle, Pfizer vaccine found 94% effective in real world

    The first big real-world study of the Pfizer/BioNTech vaccine to be independently reviewed shows the shot is highly effective at preventing COVID-19, in a potentially landmark moment for countries desperate to end lockdowns and reopen economies. Up until now, most data on the efficacy of COVID-19 vaccines has come under controlled conditions in clinical trials, leaving an element of uncertainty over how results would translate into the real world with its unpredictable variables. The research in Israel - two months into one of the world's fastest rollouts, providing a rich source of data - showed two doses of the Pfizer shot cut symptomatic COVID-19 cases by 94% across all age groups, and severe illnesses by nearly as much.